AbbVie terminated a 2020 collaboration with Jacobio Pharmaceuticals centred on the development and commercialisation of SHP2 inhibitors
The Company announced today that AbbVie has delivered the termination notice of the parties’ license and collaboration agreement (the “Agreement”) for the global development and commercialization of SHP2 inhibitors licensed by Jacobio to AbbVie under the Agreement, as part of AbbVie’s overall strategic decisions on its portfolio priorities. Following the termination of the Agreement, Jacobio will regain the global rights previously granted to AbbVie to such SHP2 inhibitors, including decision-making authority over all development, commercialization, manufacturing, regulatory activities relating to SHP2 inhibitors globally. Jacobio will also have the rights to book sales for such SHP2 inhibitors on a global basis. Both parties will collaborate to orderly transition the responsibilities under the Agreement for a period no longer than 180 days. During the transitional period, AbbVie will continue to reimburse all cost under the pre-approved development plan.
Share:
More News
“The start of patient dosing represents a huge milestone for Moleculin and importantly, the AML community,” commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “Our team remains focused on bringing clinical sites online in the U.S., Europe and Middle East and enrolling patients to build on this momentum.
“Enrollment of the first patient with HPV+ head and neck cancer in the Phase 1 ACESOT-1051 trial is an important step and is in line with our goal of identifying patient populations most likely to benefit from WEE1 inhibition,” said Philippe Pultar MD., Senior Medical Advisor and Lead WEE1 Clinical
“We are thrilled to partner with Aurigene Oncology’s exceptional team, whose deep expertise in oncology development and cell therapy manufacturing is unparalleled,” said Michal Golan Mashiach, CEO of Edity Therapeutics. “This collaboration is a pivotal step in advancing our mission to deliver transformative, curative medicines to cancer patients.”
“We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors
